Volume : 08, Issue : 02, February – 2021
42.AN OVERVIEW: IMMUNOTOXIN
Blessy M.R*, Subash Chandran M.P, Prasobh G.R, Remya S.B, Aparna P, Rohini L M, Varsha V R, Archana L R
Abstract :
Immunotoxins are hybrid molecules composed of a monoclonal antibody chemically linked to a biologic toxin. The antibody portion of the molecule directs it to a specific antigenic determinant on a target cell; the molecule is then internalized, and a cytotoxic reaction occurs. First-generation immunotoxins were made by chemically coupling toxins such as ricin (a plant toxin) or diphtheria toxin to MAbs. The early products were highly immunogenic and chemically unstable, sometimes falling apart before reaching the tumor target. These difficulties led to the development of recombinant immunotoxins that were more stably linked to the antibody until bound on the target cell surface.
Key words: Immunotoxin, Pseudomonous exotoxin, Monoclonal antibody
Cite This Article:
Please cite this article in press Blessy M.R et al, An Overview: Immunotoxin., Indo Am. J. P. Sci, 2021; 08(02).
Number of Downloads : 10
References :
1. Lord JM, Spooner RA, Roberts LM. Immunotoxins: Monoclonal antibody-toxin conjugates: A new approach to cancer therapy. In: Monoclonal antibodies: Production and application. Alan R. Liss, Inc., 1989: 193–211.
2. Knowles PP, Thorpe PE. Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B. Analytical Biochemistry 1987; 160: 440–3
3. Uckun FM, Ramakrishnan S, Houston LL. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow. J Immunol 1985; 134: 2010–16.
4. Press OW, Vitetta ES, Farr AG, Hansen JA, Martin PJ. Evaluation of ricin A-chain immunotoxins directed against human T cells. Cellular Immunology 1986; 102: 10–20.
5. Salvatore G., Beers R., Kreitman R. J., Pastan I. Improved cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res., 8: 942-944, 2002.
6. Frankel A. E., Tagge E. P., Willingham M. C. Clinical trials of targeted toxins. Semin. Cancer Biol., 6: 307-317, 1995.
7. Schindler J., Sausville E. A., Messmann R., Uhr J. W., Vitetta E. S. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin’s lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin. Cancer Res., 7: 255-258, 2001.
8. Frankel A. E., Kreitman R. J., Sausville E. A. Targeted toxins. Clin. Cancer Res., 6: 326-334, 2000.
9. vanderSpek J. C., Murphy J. R. Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptors of eukaryotic cells. Methods Enzymol., 327: 239-249, 2000.
10. Thompson, J., Stavrou, S., Weetall, M., Hexham, J. M., Digan, M. E., Wang, Z., Woo, J. H., Yu, Y., Mathias, A., Liu, Y. Y., Ma, S., Gordienko, I., Lake, P., and Neville, D. M. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng., in press.
11. Arora N., Masood R., Zheng T., Cai J., Smith D. L., Gill P. S. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res., 59: 183-188, 1999.
12. Vallera, D. A., Li, C., Jin, N., Panoskaltsis-Mortari, A., and Hall, W. A. Targeting overexpressed urokinase-type plasminogen activator receptor (uPAR) on human glioblastoma with the diphtheria toxin fusion protein DTAT in nude mice. J. Natl. Cancer Inst. (Bethesda), in press.
13. Liu S., Bugge T. H., Leppla S. H. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J. Biol. Chem., 276: 17976-17984, 2001.
14. Beers R., Chowdhury P., Bigner D., Pastan I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin. Cancer Res., 6: 2835-2843, 2000.
15. Pai-Scherf L. H., Villa J., Pearson D., Watson T., Liu E., Willingham M. C., Pastan I. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin. Cancer Res., 5: 2311-2315, 1999.